Name,Category,Begin Date,End Date,Note
Weight Loss and Fatigue,Milestones,2023-04-01,,15 lb weight loss 3 months
CT Abdomen Pelvis,Biomarker Assess,2023-04-10,,Multiple liver lesions
Liver Biopsy,Biomarker Assess,2023-04-17,,Intrahepatic cholangiocarcinoma
CA 19-9,Biomarker Assess,2023-04-20,,890 U/mL
Molecular Profiling,Biomarker Assess,2023-04-22,,Comprehensive panel sent
Staging Complete,Milestones,2023-04-25,,Stage IV liver-confined multifocal
Molecular Results,Biomarker Assess,2023-05-05,,MSI-High dMMR detected rare finding
Lynch Syndrome Workup,Biomarker Assess,2023-05-10,,MLH1 germline mutation confirmed
Genetic Counseling,Milestones,2023-05-15,,Family testing recommended
Pembrolizumab Monotherapy,Line 1 treatment,2023-05-22,2024-05-22,Keytruda for MSI-H
6-Week Scan,Biomarker Assess,2023-07-03,,Dramatic response 55% shrinkage
CA 19-9 Plummeting,Biomarker Assess,2023-07-03,,Down to 120 U/mL
12-Week Scan,Biomarker Assess,2023-08-14,,Near complete response
6-Month Scan,Biomarker Assess,2023-11-22,,Continued deep response
CA 19-9 Normal,Biomarker Assess,2023-11-22,,18 U/mL normalized
12-Month Scan,Biomarker Assess,2024-05-22,,Durable complete response
Pembrolizumab Continued,Line 1 treatment,2024-05-22,2025-05-22,Extending to 2 years total
